Category: Cancer

Targeting METTL3 Mediated m6A Methylation: A Novel Approach to Improving the Efficacy of Glioblastoma Multiforme Treatment

October 23, 2026 Janah Dia
Janah Dia Background: Glioblastoma multiforme (GBM), a WHO grade IV glioma, is the most common and aggressive primary brain tumor in adults. It is characterized by poor prognosis and high resistance rate to aggressive multimodal therapy. Standard therapy protocol involves maximal surgical resection followed by radiation and temozolomide (TMZ) chemotherapy.…
Cancer

Resting-State fMRI Changes in Motor Network Connectivity Before and After Resection of Low-Grade Gliomas Involving M1 or SMA

July 29, 2026 Chris Oake
Chris Oake Background: Low-grade gliomas (LGGs) frequently arise near eloquent motor regions such as the primary motor cortex (M1) and supplementary motor area (SMA), where even subtle postoperative weakness can significantly impair independence and quality of life1. Conventional structural imaging may underestimate the functional impact of these tumors because network-level…
Cancer Engineering Medicine Featured Abstracts Neuroscience

Integrating Survival and Functional Prognostication in Glioblastoma Treatment

July 10, 2026 Taha Hashmi
Taha Hashmi Background:  Glioblastoma (GBM) remains the most aggressive primary malignant brain tumor in adults. Standard multimodal therapy results in a median overall survival of about 14.6 months1. Current treatment strategies emphasize resection, radiotherapy, and systemic therapy. However, these modalities are often treated as separate domains rather than recognized for…
Cancer Engineering Medicine Featured Abstracts

A Cost-Benefit Analysis of the Production and Efficacy of Radionuclides in Targeted Prostate Cancer Therapy

July 7, 2026 Nathaniel J. Fernandes
Nathaniel J. Fernandes Background:  Radionuclides are radioactive (i.e., ionizing radiation-emitting) forms of elements that occur naturally or are manmade that emit high-energy particles or waves like α particles (helium nuclei), β particles (electrons), or γ rays [1, 2, 3, 5]. While some radionuclides are byproducts of nuclear reactions, others are…
Cancer Engineering Medicine Featured Abstracts

Convection‑Enhanced Delivery in Glioblastoma: Insights from Early Human Studies

July 7, 2026 John Cai
John Cai Background: Glioblastoma (GBM) is the most common malignant primary brain tumor and remains universally recurrent and uniformly fatal despite surgery, chemotherapy, and radiotherapy.3 Convection‑enhanced delivery (CED) offers an alternative treatment option by infusing therapeutics directly into the tumor and peritumoral brain under positive pressure, bypassing the blood-brain barrier…
Cancer Engineering Medicine Featured Abstracts

Failure-to-Rescue as a Mechanism of Socioeconomic Disparities in Oncologic Surgery

July 7, 2026 Abdus Sabour Shaik
Abdus Sabour Shaik Background: Failure-to-rescue (FTR), defined as death following postoperative complications, is an established measure of surgical quality to capture a healthcare system’s ability to recognize and intervene in clinical deterioration. Prior studies have demonstrated that surgical mortality variation is driven more by differences in a respective system’s FTR…
Cancer Engineering Medicine Featured Abstracts

Mechanisms of Osteolytic Bone Metastasis in Breast Cancer: RANKL Signaling, Bone Marrow Niche Programming, and RANKL-Independent Osteoclast Activation

July 6, 2026 Summer Apostalo
Summer Apostalo Background: Breast cancer metastasizes to bone in approximately 70% of patients with advanced disease, causing osteolytic destruction, pathologic fractures, hypercalcemia, and significant morbidity.¹,² A central driver of osteolysis is the RANK/RANKL/OPG signaling axis, which regulates osteoclast differentiation and fuels a self-amplifying “vicious cycle” between tumor expansion and bone…
Cancer Featured Abstracts